PHGUF Stock Chart & Stats
$1.19
$0.00(0.00%)
At close: 4:00 PM EDT
$1.19
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.89 - $2.20
Previous CloseN/A
Volume50.00
Average Volume (3M)86.00
Market Cap
$802.40M
Enterprise Value$934.02M
Total Cash (Recent Filing)$158.25M
Total Debt (Recent Filing)$126.73M
Price to Earnings (P/E)77.1
Beta0.53
Next Earnings
Oct 27, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding707,781,250
10 Day Avg. Volume260
30 Day Avg. Volume86
Financial Highlights & Ratios
PEG Ratio-2.78
Price to Book (P/B)3.72
Price to Sales (P/S)2.74
P/FCF Ratio20.17
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue2.55
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda26.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)$428.13M
Bulls Say, Bears Say
Bulls Say
Joenja GrowthJoenja is showing strong commercial traction in a rare-disease market, with rising revenue and treated patients. Planned launches in Europe and Japan, alongside pediatric expansion, broaden the addressable population and create a durable growth platform beyond RUCONEST.
Pediatric Label ExpansionThe FDA approval expands Joenja access into younger APDS patients and reinforces the product’s role across the disease population. Broader labeling can support patient identification, treatment continuity, and long-term commercial growth as pediatric diagnosis and access develop.
High-Margin ProfitabilityVery high gross margins provide substantial economic value from product sales and leave room to fund commercial infrastructure and research. The return to positive operating performance, combined with cost reductions, improves internal funding capacity for the pipeline.
Bears Say
Revenue Guidance ReductionThe reduced outlook indicates that near-term growth is weaker than previously expected, limiting operating leverage and reducing the cushion supporting pipeline investment. A low-growth period also increases reliance on Joenja execution and successful stabilization of the established franchise.
RUCONEST CompetitionRUCONEST remains a major commercial product, but competitive pressure is already reducing sales and forcing expectations for a full-year decline in U.S. revenue. Continued share or volume erosion could weigh on cash generation while Joenja scales to offset the weakness.
Leadership TransitionAn immediate CEO departure and interim leadership structure introduce execution uncertainty during a period of commercial expansion and increased R&D investment. Until a permanent successor is selected, strategic alignment and continuity of pipeline and market-launch priorities may face disruption.
Pharming Group News
PHGUF FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was $0.89 and its highest was $2.20 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is $802.40M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Oct 27, 2026 which is tomorrow.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on Jul 30, 2026. The company reported $0.002 earnings per share for the quarter, missing the consensus estimate of $0.006 by -$0.004.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Overvalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is 0.02.
How many shares outstanding does Pharming Group have?
Pharming Group has 707,781,250 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of $0.002 in its last earnings report, missing expectations of $0.006. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in PHGUF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.
PHGUF Company Deck
PHGUF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of meaningful commercial and clinical positives—most notably strong Joenja growth, resilient RUCONEST patient metrics, and near‑term clinical catalysts—against tangible near‑term headwinds including a $30M revenue guidance reduction, RUCONEST year‑over‑year sales decline, manufacturing inventory impairments, and operating cash outflows. Management emphasized cost discipline, maintained positive operating profitability in the quarter, and outlined multiple growth levers (pediatric and geographic expansion for Joenja, two Phase II readouts in Q4, and a 2027 pivotal readout for napazimone). Given the balance of clear growth drivers and pipeline upside against notable short‑term financial and operational challenges, the tone is constructive but cautious.View all PHGUF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
1.35% Mutual Funds
― Other Institutional Investors
95.12% Public Companies and
Individual Investors